Breast Cancer
Conference Coverage
PD-L1 cutoff for pembrolizumab in mTNBC confirmed
PD-L1 CPS of at least 10 improves overall survival by 28%-29%. Further analysis of responses to pembrolizumab plus chemotherapy in metastatic TNBC...
News
Pembrolizumab improves event-free survival in early TNBC
Neoadjuvant pembrolizumab benefits early TNBC patients regardless of disease stage and nodal status. Event-free survival improved by about 35%...
Conference Coverage
Antibiotic use associated with triple-negative breast cancer mortality
Antimicrobials can decrease circulating and tumor-infiltrating lymphocytes that effect the immune repertoire and in turn survival.
Conference Coverage
Omega-3 supplements may impact breast cancer risk
Two small studies suggest gut microbiota changes could influence susceptibility.
Conference Coverage
Women struggle with benzodiazepine addiction post chemotherapy treatment
Sedatives like benzodiazepines are used to control nausea, anxiety, and insomnia during chemotherapy treatment, but overuse and failing to taper...
Conference Coverage
‘Surprising’ lack of benefit to adding palbociclib to endocrine therapy in early HR+/HER2– breast cancer
Two years of adjuvant palbociclib with endocrine therapy failed to improve invasive disease-free survival in patients with stage II-III HR-...
News
The evolving HER2+ metastatic breast cancer landscape: Novel agents and promising combination therapies
“The fact that we’re now talking about fourth- and fifth-line therapies for HER2-positive MBC represents a major advance in the management of...
Conference Coverage
Ongoing HER2 breast cancer therapy may cost an additional $68,000 per patient
A Canadian study suggests that significant increases in cost per patient can be expected if funding policies don’t evolve to meet treatment needs...
Conference Coverage
Vitamin D counters bone density loss with aromatase inhibitors
Researchers found no difference in bone mineral decline among breast cancer patients treated with aromatase inhibitors and those treated with...
Conference Coverage
Metformin does not improve outcomes in early breast cancer